Viking Therapeutics, a clinical-stage biopharmaceutical company headquartered in San Diego, California, has recently released its 10-K report, providing valuable insights into its financial condition and operations. The company is primarily focused on developing novel therapies for metabolic and endocrine disorders, with its lead drug candidate, VK2809, in Phase IIb clinical trials to treat patients with non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Additionally, Viking Therapeutics is developing VK5211, VK0612, VK2735, and VK0214 for various metabolic and endocrine disorders.
The 10-K report highlights the company's significant achievements in its clinical trials. Viking Therapeutics announced the initiation and completion of several Phase 1 and Phase 2 clinical trials for VK2735, a novel dual agonist for the potential treatment of metabolic disorders such as obesity. The company reported positive results, including statistically significant reductions in body weight among patients receiving VK2735.
Moreover, Viking Therapeutics announced the initiation of Phase 3 clinical studies to evaluate the subcutaneous formulation of VK2735, demonstrating its commitment to advancing the development of its drug candidates. The report also details the company's progress in its other programs, such as VK2809 for non-alcoholic steatohepatitis, and VK0214 for X-linked adrenoleukodystrophy, with positive results and milestones achieved in various clinical trials.
Financially, Viking Therapeutics disclosed that it has not generated any revenue to date. The company's research and development expenses for the year ended December 31, 2025, amounted to $345.0 million, primarily related to conducting clinical trials for its drug candidates. The report outlines the breakdown of research and development expenses, including costs incurred for employee and consultant-related expenses, agreements with investigative sites and CROs, payments to third-party manufacturers, and license fees paid to third parties for the use of their intellectual property.
Following these announcements, the company's shares moved 6.4%, and are now trading at a price of $33.92. Check out the company's full 10-K submission here.
